Danaher Corporation $DHR Shares Purchased by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Danaher Corporation (NYSE:DHR) by 8.3% in the second quarter, Holdings Channel reports. The firm owned 41,182 shares of the conglomerate’s stock after buying an additional 3,145 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Danaher were worth $8,133,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Invesco Ltd. raised its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after acquiring an additional 163,332 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is owned by company insiders.

Danaher Stock Performance

NYSE DHR opened at $223.03 on Monday. The stock has a 50-day simple moving average of $202.73 and a two-hundred day simple moving average of $198.57. The firm has a market capitalization of $157.54 billion, a P/E ratio of 45.99, a PEG ratio of 3.41 and a beta of 0.77. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. Guggenheim restated a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Bank of America reduced their target price on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Barclays raised their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a research note on Thursday. Finally, UBS Group reduced their target price on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.